Graft Versus Host Disease – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Graft versus host disease (GVHD) is a potentially life-threatening complication of allogenic hematopoietic stem cell transplantation (HSCT). Steroids have been the first-line therapy for the prevention and treatment of GVHD for decades, and since 2019, three therapies have been approved for steroid-refractory GVHD: Jakafi / Jakavi (ruxolitinib), Imbruvica (ibrutinib), and Rezurock (belumosudil). Despite these options, there is a substantial need for more-effective therapies for steroid-refractory disease, as well as better first-line and prophylactic treatments for GVHD. In this content, we explore the clinical and commercial potential of key current and emerging therapies for GVHD.
Questions answered
- How large is the GVHD population, and how will it change through 2033? What percentage of the GVHD population receive drug treatment?
- What is the current treatment landscape and medical practice in GVHD, and what are the greatest unmet needs according to experts?
- Which pipeline products are the most promising, and what sales/uptake could they secure in GVHD? Which therapies of note are progressing in earlier phases?
- What are the drivers and constraints in the GVHD market, and how will the market evolve over the forecast period?
Content highlights
Geography: United States and EU5
Primary research: Six country-specific interviews with thought-leading GVHD specialists. Supported by survey data collected for this study
Epidemiology: Diagnosed incident cases of acute and chronic GVHD, diagnosed incident cases of acute GVHD by grade, drug-treated cases of GVHD by country
Forecast: Drug-level sales and patient share of key GVHD therapies through 2033
Drug treatments: Coverage of key current and emerging therapies
Product description
Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.
Key feature
Niche & Rare Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Graft Versus Host Disease - Landscape & Forecast - Niche & Rare Disease Landscape & Forecast (US/EU5)
- Content announcement
- Executive Summary
- Commercial Outlook and Forecast
- Disease Context
- Epidemiology
- Key takeaways
- Diagnosed events of allogeneic hematopoietic stem cell transplantation
- Diagnosed incident cases of acute graft versus host disease by severity
- Diagnosed incident cases of chronic graft versus host disease by severity
- Diagnosed prevalent cases of chronic graft versus host disease by severity
- Drug-treated cases of graft versus host disease
- Key takeaways
- Current Treatment
- Emerging Therapies
- Drug Pipeline
- Methodology
- Bottom-up forecasting overview
- Bottom-up forecast key events and assumptions
- Market events impacting the graft versus host disease forecast
- Drug-treatment rate assumptions in graft versus host disease
- Forecast market authorization and/or launch dates of key emerging therapies for the treatment of graft versus host disease
- Generic erosion
- Generic erosion assumptions
- Biosimilar erosion
- Biosimilar erosion assumptions
- Dosing assumptions of key therapies in graft versus host disease
- Days of therapy and compliance
- Emerging therapy prices
- Prices of key current and emerging therapies used to treat graft versus host disease
- Bottom-up forecast methodology
- Primary market research
- Appendix
